Bioprospect linking with Solagran is the bigest news for BPO. See the anouncement on asx ths morning. Years of hard work coming to fruition, SLA up 10% and welcoming BPO partnership, news is long but worth the read, particularly financials. This is one piece of the jig saw coming together and a most welcome one at that. BPO's product Termilone has many other applications and this outstanding news is for just one group of applications which has world wide company making significance.
BPO Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
